ENTXのチャート
ENTXの企業情報
| symbol | ENTx |
|---|---|
| 会社名 | Entera Bio Ltd （エンテラ・バイオ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Entera Bio Ltd is an Israel-based product-focused biotechnology company that specializes in the oral delivery of large molecules and biologics. The Company conducts clinical trials on its proprietary technology which allows oral delivery of large molecules and biologics while enhancing their absorption in the gastrointestinal (GI) tract. Entera Bio Ltd's technology addresses the major problems of oral drug delivery of large molecule active pharmaceutical ingredients (APIs). Most large molecules cannot be administered orally as they are not readily absorbed by the gastrointestinal tract and are rapidly degraded by a myriad of enzymes and acids in the gastrointestinal tract. The Company’s proprietary technologies act synergistically to transport and protect large molecules. The Company develops drugs for hypoparathyroidism osteoporosis and bone healing. エンテラ・バイオはイスラエルのバイオ医薬品企業。有効な治療法が確立されていない疾患のための治療薬の発見、開発および商品化に焦点を当て事業を行う。主に副甲状腺機能低下症および骨粗しょう症の治療薬として経口カプセルの開発を手掛ける。主要製品候補には、副甲状腺ホルモンの治療薬EB612や、骨粗しょう症および癒着不能骨折の治療薬EB613などがある。 Entera is a leader in the development of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company's proprietary, oral drug delivery technology is designed to address the technical challenges of poor absorption, high variability, and the inability to deliver large molecules to the targeted location in the body through the use of a synthetic absorption enhancer to facilitate the absorption of large molecules, and protease inhibitors to prevent enzymatic degradation and support delivery to targeted tissues. The Company's most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in Phase 2 clinical development. Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc. |
| 本社所在地 | Kiryat Hadassah Minrav Building - Fifth Floor Jerusalem 9112002 ISR |
| 代表者氏名 | Gerald M. Lieberman ジェラルド・M・リーバーマン |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | ― |
| 設立年月日 | 40330 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2018年 |
| 従業員数 | － |
| url | www.enterabio.com |
| nasdaq_url | https://www.nasdaq.com/symbol/entx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -12.65700 |
| 終値（lastsale） | 5.85 |
| 時価総額（marketcap） | 66855672 |
| 時価総額 | 時価総額（百万ドル） 60.11296 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 88.47196 |
| 当期純利益 | 当期純利益（百万ドル） -10.02400 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Entera Bio Ltd revenues was not reported. Net loss decreased 31% to $2.6M. Lower net loss reflects FV Adjustments of Financial Investments increase from $479K to $2.9M (income) GENERAL AND ADMINISTRATIVE EXPENSES (INC decrease of 70% to $854K (expense) Other financial expenses (income) net increase from $71K (expense) to $23K (income). |
ENTXのテクニカル分析
ENTXのニュース
Parathyroid Hormone Global Market Report 2021: COVID-19 Growth And Change To 2030 2021/09/27 11:35:00 Intrado Digital Media
Major players in the parathyroid hormone market are Pfizer Inc, Eli Lilly and Company, Radius Health Inc, Shire, Ascendis Pharma, Entera Bio Ltd. , and Extend Biosciences Inc. The global parathyroid hormone market is expected to grow from $1. Major players in the parathyroid hormone market are Pfizer Inc, Eli Lilly and Company, Radius Health Inc, Shire, Ascendis Pharma, Entera Bio Ltd. , and Extend Biosciences Inc. The global parathyroid hormone market is expected to grow from $1.
Entera Bio Selected for Late Breaking Oral Presentation of Phase 2 6-Month Osteoporosis Data at ASBMR 2021 Annual Meeting 2021/09/01 12:30:00 Intrado Digital Media
Second of Two Presentations to be Delivered by Entera
Knoll Capital Management, LLC Buys Entera Bio, Annovis Bio Inc, Advanced Micro Devices Inc 2021/08/24 19:38:17 GuruFocus
Related Stocks: ENTX , SVM , SILV , ANVS , AMD , AGTC ,
Entera Bio to Conduct Annual Shareholders Meeting on October 4, 2021 2021/08/23 15:00:00 Intrado Digital Media
BOSTON and JERUSALEM, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced it will host its annual shareholders meeting on Monday, October 4, 2021.
Entera Bio to Present at H.C. Wainwright 23rd Annual Global Investment Conference 2021/08/23 12:30:00 Intrado Digital Media
BOSTON and JERUSALEM, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the Companys CEO Spiros Jamas will present at the H.C. Wainwright 23rd Annual Global Investment Conference on Monday, September 13, 2021 at 3:30 pm ET at the Lotte New York Palace Hotel. The hybrid in-person and virtual conference will take place from September 1315, 2021. In addition to the presentation, management will conduct 1-on-1 meetings with investors. For more information on the conference or to register, visit: HCW Events .
Entera Bio Selected for Late Breaking Oral Presentation of Phase 2 6-Month Osteoporosis Data at ASBMR 2021 Annual Meeting 2021/09/01 12:30:00 Intrado Digital Media
Second of Two Presentations to be Delivered by Entera
Knoll Capital Management, LLC Buys Entera Bio, Annovis Bio Inc, Advanced Micro Devices Inc 2021/08/24 19:38:17 GuruFocus
Related Stocks: ENTX , SVM , SILV , ANVS , AMD , AGTC ,
Entera Bio to Conduct Annual Shareholders Meeting on October 4, 2021 2021/08/23 15:00:00 Intrado Digital Media
BOSTON and JERUSALEM, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced it will host its annual shareholders meeting on Monday, October 4, 2021.
Entera Bio to Present at H.C. Wainwright 23rd Annual Global Investment Conference 2021/08/23 12:30:00 Intrado Digital Media
BOSTON and JERUSALEM, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the Companys CEO Spiros Jamas will present at the H.C. Wainwright 23rd Annual Global Investment Conference on Monday, September 13, 2021 at 3:30 pm ET at the Lotte New York Palace Hotel. The hybrid in-person and virtual conference will take place from September 1315, 2021. In addition to the presentation, management will conduct 1-on-1 meetings with investors. For more information on the conference or to register, visit: HCW Events .
Entera Bio Ltd. (ENTX) CEO Spiros Jamas on Q2 2021 Results - Earnings Call Transcript 2021/08/16 17:45:04 Seeking Alpha
Knoll Capital Management, LLC Buys Entera Bio, Annovis Bio Inc, Advanced Micro Devices Inc 2021/08/24 19:38:17 GuruFocus
Related Stocks: ENTX , SVM , SILV , ANVS , AMD , AGTC ,
Entera Bio to Conduct Annual Shareholders Meeting on October 4, 2021 2021/08/23 15:00:00 Intrado Digital Media
BOSTON and JERUSALEM, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced it will host its annual shareholders meeting on Monday, October 4, 2021.
Entera Bio to Present at H.C. Wainwright 23rd Annual Global Investment Conference 2021/08/23 12:30:00 Intrado Digital Media
BOSTON and JERUSALEM, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the Companys CEO Spiros Jamas will present at the H.C. Wainwright 23rd Annual Global Investment Conference on Monday, September 13, 2021 at 3:30 pm ET at the Lotte New York Palace Hotel. The hybrid in-person and virtual conference will take place from September 1315, 2021. In addition to the presentation, management will conduct 1-on-1 meetings with investors. For more information on the conference or to register, visit: HCW Events .